Adjuvant therapy for gastric cancer: a reality at last.
Curr Gastroenterol Rep., Dec;2(6):478-81 (2000)
Low-dose trimetrexate glucuronate and protracted 5-fluorouracil infusion in previously untreated patients with advanced pancreatic cancer.
Ann. Oncol., Apr;13(4):582-8 (2002)
Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer.
J. Nucl. Med., Apr;46(4):587-95 (2005)
Prolonged nausea and vomiting after high dose chemotherapy and autologous peripheral stem cell transplantation in the treatment of high risk breast carcinoma.
Cancer., May;79(9):1698-702 (1997)
CT colonography: value of scanning in both the supine and prone positions.
AJR Am J Roentgenol., Mar;172(3):595-9 (1999)
Male breast cancer.
Am. J. Clin. Pathol., Oct;102(4 Suppl 1):S25-30 (1994)
Gastrin-releasing peptide-induced expression of prostaglandin synthase-2 in Swiss 3T3 cells.
Prostaglandins., Nov;54(5):757-68 (1997)
Metastasis in colorectal cancer: what makes the tumor aggressive?
Eur J Surg Suppl., (582):104-10 (1998)
Improved imaging and the clinician: the role of positron emission tomography in the management of colorectal cancer.
Mol Imaging Biol., 6(4):208-13 (2004)
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction.
Br. J. Cancer., Sep;105(6):760-5 (2011)
EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study.
Gastrointest. Endosc., Feb;75(2):332-8 (2012)
Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Clin. Cancer Res., Mar;16(5):1509-19 (2010)
An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study.
Cancer., May;106(9):1908-16 (2006)
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.
J. Clin. Oncol., Nov;22(22):4456-62 (2004)
Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.
J. Clin. Oncol., Mar;21(5):807-14 (2003)
A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.
Clin. Cancer Res., Feb;9(2):555-61 (2003)
Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia.
Oncology (Williston Park, N.Y.)., Sep;17(9 Suppl 8):13-5 (2003)
Gastrointestinal toxicity or irinotecan.
Oncology (Williston Park, N.Y.)., Aug;12(8 Suppl 6):72-8 (1998)
Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis.
Hum. Pathol., Feb;30(2):123-9 (1999)
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
J. Clin. Oncol., Jun;23(16):3697-705 (2005)